Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.

van Iersel MLPS, Rossenu S, de Greef R, Waskin H.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02465-17. doi: 10.1128/AAC.02465-17. Print 2018 Jul.

2.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382. No abstract available.

PMID:
29029280
3.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3501.

PMID:
28961714
4.

Erratum for Kersemaekers et al., Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4426. doi: 10.1128/AAC.01001-16. Print 2016 Jul. No abstract available.

5.

Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, van Iersel ML.

Antimicrob Agents Chemother. 2015;59(6):3385-9. doi: 10.1128/AAC.05000-14. Epub 2015 Mar 30.

6.

Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2015 Feb;59(2):1246-51. doi: 10.1128/AAC.04223-14. Epub 2014 Dec 15. Erratum in: Antimicrob Agents Chemother. 2016 Jul;60(7):4426.

7.

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H.

Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.

8.

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM.

Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5. doi: 10.1128/AAC.02448-13. Epub 2014 May 5.

9.

Metabolism and excretion of asenapine in healthy male subjects.

van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, Spaans E, Peeters PA, Delbressine LP, van Iersel ML.

Drug Metab Dispos. 2011 Apr;39(4):580-90. doi: 10.1124/dmd.110.036715. Epub 2010 Dec 22.

PMID:
21177986
10.

Selective tissue distribution of tibolone metabolites in mature ovariectomized female cynomolgus monkeys after multiple doses of tibolone.

Verheul HA, van Iersel ML, Delbressine LP, Kloosterboer HJ.

Drug Metab Dispos. 2007 Jul;35(7):1105-11. Epub 2007 Apr 9.

PMID:
17420283
11.

Pharmacokinetic parameters of tibolone and metabolites in plasma, urine, feces, and bile from ovariectomized cynomolgus monkeys after a single dose or multiple doses of tibolone.

Verheul HA, Timmer CJ, van Iersel ML, Delbressine LP, Kloosterboer HJ.

Drug Metab Dispos. 2007 Jul;35(7):1112-8. Epub 2007 Apr 9.

PMID:
17420282
12.

Inhibition of human glutathione S-transferase P1-1 by the flavonoid quercetin.

van Zanden JJ, Ben Hamman O, van Iersel ML, Boeren S, Cnubben NH, Lo Bello M, Vervoort J, van Bladeren PJ, Rietjens IM.

Chem Biol Interact. 2003 May 6;145(2):139-48.

PMID:
12686490
13.

Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases.

Boersma MG, van der Woude H, Bogaards J, Boeren S, Vervoort J, Cnubben NH, van Iersel ML, van Bladeren PJ, Rietjens IM.

Chem Res Toxicol. 2002 May;15(5):662-70.

PMID:
12018987
14.

Structure activity relationships for the chemical behaviour and toxicity of electrophilic quinones/quinone methides.

Rietjens IM, Awad HM, Boersma MG, van Iersel ML, Vervoort J, Van Bladeren PJ.

Adv Exp Med Biol. 2001;500:11-21. No abstract available.

PMID:
11764920
15.

The role of biotransformation in dietary (anti)carcinogenesis.

van Iersel ML, Verhagen H, van Bladeren PJ.

Mutat Res. 1999 Jul 15;443(1-2):259-70. Review.

PMID:
10415444
16.

Interactions of prostaglandin A2 with the glutathione-mediated biotransformation system.

van Iersel ML, Cnubben NH, Smink N, Koeman JH, van Bladeren PJ.

Biochem Pharmacol. 1999 Jun 15;57(12):1383-90.

PMID:
10353259
17.

GSTP1-1 stereospecifically catalyzes glutathione conjugation of ethacrynic acid.

van Iersel ML, van Lipzig MM, Rietjens IM, Vervoort J, van Bladeren PJ.

FEBS Lett. 1998 Dec 11;441(1):153-7.

18.

Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1.

van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ.

Chem Biol Interact. 1997 Dec 12;108(1-2):67-78.

PMID:
9463521
19.

In vitro inhibition of rat and human glutathione S-transferase isoenzymes by disulfiram and diethyldithiocarbamate.

Ploemen JP, van Iersel ML, Wormhoudt LW, Commandeur JN, Vermeulen NP, van Bladeren PJ.

Biochem Pharmacol. 1996 Jul 26;52(2):197-204.

PMID:
8694843
20.

Metabolism of [3-14C] coumarin by human liver microsomes.

van Iersel ML, Henderson CJ, Walters DG, Price RJ, Wolf CR, Lake BG.

Xenobiotica. 1994 Aug;24(8):795-803.

PMID:
7839702
21.

Case-control study on fecapentaene excretion and adenomatous polyps in the colon and rectum.

de Kok TM, Pachen D, van Iersel ML, Baeten CG, Engels LG, ten Hoor F, Kleinjans JC.

J Natl Cancer Inst. 1993 Aug 4;85(15):1241-4. No abstract available.

PMID:
8331685
22.

In vitro study on the effects of fecal composition on fecapentaene kinetics in the large bowel.

de Kok TM, van Iersel ML, ten Hoor F, Kleinjans JC.

Mutat Res. 1993 Jun;302(2):103-8.

PMID:
7684504

Supplemental Content

Loading ...
Support Center